Literature DB >> 12707028

Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.

Leticia Quintanilla-Martinez1, Marcus Kremer, Katja Specht, Julia Calzada-Wack, Michaela Nathrath, Robert Schaich, Heinz Höfler, Falko Fend.   

Abstract

The signal transducer and activator of transcription molecules (Stats) play key roles in cytokine-induced signal transduction. Recently, it was proposed that constitutively activated Stat 3 (Stat 3 phosphorylated) contributes to the pathogenesis of multiple myeloma (MM) by preventing apoptosis and inducing proliferation. The study aim was to investigate Stat 3 activation in a series of multiple myeloma (MM) cases and its effect on downstream targets such as the anti-apoptotic proteins Bcl-xL, Mcl-1, and Bcl-2, and the cell-cycle protein cyclin D1. Forty-eight cases of MM were analyzed. Immunohistochemistry was performed on paraffin sections using antibodies against cyclin D1, Bcl-2, Bcl-xL, Mcl-1, p21, Stat 3, and Stat 3 phosphorylated (P). Their specificity was corroborated by Western blot analysis using eight human MM cell lines as control. The proliferation rate was assessed with the antibody MiB1. In addition, the mRNA levels of cyclin D1 and Stat 3 were determined by quantitative real-time reverse transcriptase-polymerase chain reaction of paraffin-embedded microdissected tissue. Three different groups determined by the expression of Stat 3P and cyclin D1 (protein and mRNA) were identified: group 1, Stat 3-activated (23 cases, 48%). All cases revealed nuclear expression of Stat 3P. No elevation of Stat 3 mRNA was identified in any of the cases. Three cases in this group showed intermediate to low cyclin D1 protein and mRNA expression. Group 2 included 15 (31%) cases with cyclin D1 staining and lack of Stat 3P. All cases showed intermediate to high levels of cyclin D1 mRNA expression. Group 3 included 10 (21%) cases with no expression of either cyclin D1 or Stat 3P. High levels of anti-apoptotic proteins Bcl-xL and Mcl-1 were identified in 89% and 100% of all cases, respectively. In contrast to Bcl-xL and Mcl-1, the expression of Bcl-2 showed an inverse correlation with proliferation rate (P: 0.0003). No significant differences were found between the three groups in terms of proliferation rate or expression of anti-apoptotic proteins. However, cyclin D1+ cases were always well differentiated and were more likely to show a lymphoplasmocytoid differentiation (chi-square = 9.55). Overall, constitutive activation of Stat 3 was found in almost half (48%) of the investigated MM cases. However, this does not seem to have a major impact on the expression of anti-apoptotic proteins and proliferation. We showed that cyclin D1 overexpression and Stat 3 activation are, mutually exclusive events in MM (P = 0.0066). The universal expression of Mcl-1, independent of activated Stat 3, suggests that its expression is constitutive and that it might play an important role in the pathogenesis of MM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707028      PMCID: PMC1851203          DOI: 10.1016/S0002-9440(10)64278-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

Review 1.  Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Authors:  John J O'Shea; Massimo Gadina; Robert D Schreiber
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism.

Authors:  F Bienvenu; H Gascan; O Coqueret
Journal:  J Biol Chem       Date:  2001-02-20       Impact factor: 5.157

3.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

Review 4.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

5.  Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Authors:  D Puthier; S Derenne; S Barillé; P Moreau; J L Harousseau; R Bataille; M Amiot
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

6.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Authors:  G Pruneri; S Fabris; L Baldini; N Carboni; S Zagano; M A Colombi; G Ciceri; L Lombardi; M Rocchi; R Buffa; A T Maiolo; A Neri
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 7.  The role of STATs in transcriptional control and their impact on cellular function.

Authors:  J Bromberg; J E Darnell
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

8.  IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.

Authors:  D Puthier; R Bataille; M Amiot
Journal:  Eur J Immunol       Date:  1999-12       Impact factor: 5.532

9.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Authors:  Hervé Avet-Loiseau; Thierry Facon; Bernard Grosbois; Florence Magrangeas; Marie-José Rapp; Jean-Luc Harousseau; Stéphane Minvielle; Régis Bataille
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

10.  Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.

Authors:  Muneyuki Masuda; Masumi Suzui; Ryuji Yasumatu; Torahiko Nakashima; Yuichiro Kuratomi; Kaoru Azuma; Kichinobu Tomita; Sohtaro Komiyama; I Bernard Weinstein
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  42 in total

Review 1.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

Review 2.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 3.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

4.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  Bcl-xl expression in multiple myeloma.

Authors:  S D P W M Peeters; S Hovenga; S Rosati; E Vellenga
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

6.  Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer.

Authors:  Natasa Anastasov; Margit Klier; Ina Koch; Daniela Angermeier; Heinz Höfler; Falko Fend; Leticia Quintanilla-Martinez
Journal:  J Hematop       Date:  2008-11-19       Impact factor: 0.196

7.  IL-6 polymorphism in non-small cell lung cancer: a prognostic value?

Authors:  Mónica Gomes; Ana Coelho; António Araújo; Andreia Azevedo; Ana Luísa Teixeira; Raquel Catarino; Rui Medeiros
Journal:  Tumour Biol       Date:  2015-01-09

8.  The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate.

Authors:  Ravi P Sahu; Sanjay K Srivastava
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

9.  Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas.

Authors:  Zhaoyang Li; Chen-Feng Qi; Dong-Mi Shin; Adriana Zingone; Helen J Newbery; Alexander L Kovalchuk; Catherine M Abbott; Herbert C Morse
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

10.  Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Authors:  R Brown; S Yang; C Weatherburn; J Gibson; P J Ho; H Suen; D Hart; D Joshua
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.